Other languages Biomind Labs Inc.

Equities

BMND.F

CA0907021012

End-of-day quote OTC Markets Other stock markets 03:30:00 04/04/2024 am IST			5-day change	1st Jan Change
0.11 ^USD	-.--%		-.--%	+10.00%

2023	Biomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical Applications	CI
2023	Biomind Labs Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical Applications	14/23/14
Biomind Labs Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16
An unknown buyer acquired 27.09% stake in Biomind Labs Inc. (OTCPK:BMND.F) from Union Acquisition Group, LLC for $14.1 million.	27/23/27
Biomind Labs Inc. Announces the Start of the First-Ever Clinical Trial Targeting Depression and Anxiety in Alzheimer’S Disease with A Proprietary Formulation Based on 5-Meo-Dmt	25/23/25
Biomind Labs Inc. Auditor Raises 'Going Concern' Doubt	31/23/31
Biomind Labs Inc. Announces the Completion of the First Sublingual Psychedelic Formulation for Its Drug Candidate Bmnd08 for Depression and Anxiety in Alzheimer’s Disease	28/22/28
Biomind Labs Inc. Announces FDA Investigational New Drug Clearance for its New Chemical Entity Triptax™ Targeting Treatment-Resistant Depression	15/22/15
Biomind Labs Inc. Announces Positive Initial Results From Its Phase II Trial on its BMND01 Candidate for Treatment Resistant Depression	04/22/04
Biomind Labs Announces Pre-Ind Meeting Request Granted by FDA for Its New Chemical Entity Triptax Targeting Treatment-Resistant Depression	11/22/11
Biomind Labs and Queen's University of Belfast Receives Controlled Substances License to Commence the Production of A Novel Transdermal Drug Delivery System	27/22/27
Biomind Labs Announces Completion of Dosing in Phase II Trial of its DMT-Based Inhaled Formulation Bmnd01 for Treatment-Resistant Depression	21/22/21
Biomind Labs Inc. Receives Approval for A Third Phase II Clinical Trial for Its 5-Meo-Dmt Based Bmnd08 Candidate for Treatment of Depression and Anxiety in Alzheimer’s Disease	26/22/26
Crosswinds Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	16/22/16
Biomind Labs Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	16/22/16
Biomind Labs Doses First Subject in Phase I/IIa Clinical Trial of Its DMT-Based Inhaled Formulation BMND01 for Treatment-Resistant Depression	26/22/26
Biomind Labs Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	01/22/01
Biomind Labs to Commence Commercial Clinical Trial on Its Proprietary Mescaline Candidate BMND06	24/22/24
Biomind Labs Opens a New Clinical Psychedelic Research Facility	17/22/17
Biomind Labs Inc. Receives Approval for a Second Phase II Clinical Trial for Treatment-resistant Depression	09/22/09
Biomind Labs Inc. Announces Positive Results on in Vivo Studies for its Proprietary Drug Candidate BMND07	03/22/03

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Biomind Labs Inc.

Equities

BMND.F

CA0907021012

Other languages

Filters